ZYNE - Zynerba Pharmaceuticals GAAP EPS of -$0.20 beats by $0.03

• Zynerba Pharmaceuticals press release ( NASDAQ: ZYNE ): Q3 GAAP EPS of -$0.20 beats by $0.03 .
• As of September 30, 2022, cash and cash equivalents were $55.9 million, compared to $67.8 million as of December 31, 2021.
• Management believes that the Company’s cash and cash equivalents are sufficient to fund operations and capital requirements into the first quarter of 2024.
• Top-line results from the Company’s confirmatory pivotal Phase 3 RECONNECT trial of Zygel in patients with FXS are expected in the second half of 2023.
• Shares +5.78% PM.

For further details see: